Research Chemical Designation & Liability

Compounds indexed in the MinMaxMuscle archive are strictly for laboratory research and development. They are NOT approved for human consumption. Theoretical dosing data is aggregated from clinical literature and must not be construed as medical instruction. Professional medical consultation is mandatory prior to any research application.

Full Disclaimer
Archive Identifier

Mod-GRF(1-29)

Growth Hormone Secretagogues

Molecular Dossier

  • Rank Index: 63
  • Status: Research Only
  • What does this mean?
  • Molecular Structure: MW: 3367.9 Da | GHRH(1-29) with 4 substitutions (His2Ala, Val8Ala, Gln15Ala, Ala22Glu)

About Mod-GRF(1-29)

Modified GHRH(1-29) analogue with four amino acid substitutions that dramatically extend half-life from 2 minutes to approximately 30 minutes. When combined with Ipamorelin, produces synergistic GH pulses that mimic natural pulsatile GH release patterns. Considered the cleanest GHRH analogue with minimal side effects.

Clinical Focus

Growth Hormone Release, GH Pulse Amplification, Recovery

Archival Aliases

CJC-1295 no DAC, Modified GRF, Sermorelin Analogue, Tetrasubstituted GRF

Frequently Asked Questions

Clinical Data Matrix

Parameter Clinical Value
Molecular Weight MW: 3367.9 Da | GHRH(1-29) with 4 substitutions (His2Ala, Val8Ala, Gln15Ala, Ala22Glu)
Primary Pathway Growth Hormone Secretagogues
Research Phase Research Only

Clinical Pros

  • Highly selective receptor modulation
  • Documented efficacy in Phase II trials
  • Minimal systemic cross-reactivity

Research Limitations

  • Limited long-term human data
  • Strict storage and reconstitution requirements
  • Potential for acute homeostatic feedback loops

Community Discussion

Share your questions and experiences with other researchers in the forum.

Discuss in Forum

Clinical Reference Nodes

[REF 1] pubmed.ncbi.nlm.nih.gov
[REF 2] pubmed.ncbi.nlm.nih.gov

Data Verified: 2026-04-14

Synergistic Matrix